Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has granted Restricted Stock Units (RSUs) representing 4,500 shares of common stock to three new non-executive employees. The RSUs were approved by the company's Compensation Committee as inducement awards under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. These awards fall under the Neuronetics 2020 Inducement Plan.
Neuronetics (NASDAQ: STIM), un'azienda di tecnologia medica specializzata nei disturbi neuro-sanitari, ha concesso Restricted Stock Units (RSU) pari a 4.500 azioni ordinarie a tre nuovi dipendenti non esecutivi. Le RSU sono state approvate dal Comitato per la Remunerazione della società come premi di incentivo ai sensi della Regola NASDAQ 5635(c)(4). Le RSU matureranno in quote uguali nel corso di tre anni, rispettivamente al primo, secondo e terzo anniversario della data di assegnazione, subordinatamente alla continuità del rapporto di lavoro. Questi premi rientrano nel Piano di Incentivazione Neuronetics 2020.
Neuronetics (NASDAQ: STIM), una empresa de tecnología médica especializada en trastornos neuro-sanitarios, ha otorgado Unidades de Acciones Restringidas (RSU) que representan 4,500 acciones ordinarias a tres nuevos empleados no ejecutivos. Las RSU fueron aprobadas por el Comité de Compensación de la compañía como premios de incentivo bajo la Regla de Listado NASDAQ 5635(c)(4). Las RSU se consolidarán en cuotas iguales durante tres años, en el primer, segundo y tercer aniversario de la fecha de concesión, condicionado a la continuidad del empleo. Estos premios forman parte del Plan de Incentivos Neuronetics 2020.
Neuronetics (NASDAQ: STIM)는 신경 건강 장애를 전문으로 하는 의료 기술 회사로, 세 명의 신임 비임원 직원에게 4,500주의 보통주에 해당하는 제한 주식 단위(RSUs)를 부여했습니다. 이 RSU는 NASDAQ 상장 규칙 5635(c)(4)에 따른 유인 보상으로 회사 보상위원회의 승인을 받았습니다. RSU는 부여일로부터 1년, 2년, 3년째 되는 해에 각각 동일한 비율로 베스팅되며, 계속 고용 상태를 조건으로 합니다. 이 보상은 Neuronetics 2020 유인 계획에 포함됩니다.
Neuronetics (NASDAQ : STIM), une société de technologie médicale spécialisée dans les troubles neuro-sanitaires, a accordé des unités d’actions restreintes (RSU) représentant 4 500 actions ordinaires à trois nouveaux employés non cadres. Les RSU ont été approuvées par le comité de rémunération de l’entreprise en tant que récompenses d’incitation conformément à la règle NASDAQ 5635(c)(4). Les RSU seront acquises par tranches égales sur trois ans, aux premier, deuxième et troisième anniversaires de la date d’attribution, sous réserve de la poursuite de l’emploi. Ces récompenses font partie du Plan d’incitation Neuronetics 2020.
Neuronetics (NASDAQ: STIM), ein Medizintechnikunternehmen, das sich auf neurogesundheitliche Störungen spezialisiert hat, hat drei neuen nicht geschäftsführenden Mitarbeitern Restricted Stock Units (RSUs) im Umfang von 4.500 Stammaktien gewährt. Die RSUs wurden vom Vergütungsausschuss des Unternehmens als Anreizprämien gemäß NASDAQ-Notierungsregel 5635(c)(4) genehmigt. Die RSUs werden in gleichen Raten über drei Jahre am ersten, zweiten und dritten Jahrestag des Gewährungsdatums fällig, vorbehaltlich einer fortgesetzten Beschäftigung. Diese Prämien fallen unter den Neuronetics 2020 Inducement Plan.
- None.
- None.
MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company’s common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
The RSU grants vest ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
About Neuronetics and Greenbrook
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 7.1 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
What is the size of Neuronetics (STIM) RSU grant announced in May 2025?
How do the STIM RSUs vest for the new employees?
Under which plan were the Neuronetics (STIM) inducement awards granted?
What is Neuronetics' (STIM) business focus?
